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Abstract
Background: Genuine uncertainty on superiority of one intervention over the other is called equipoise. Physician-
investigators in randomized controlled trials (RCT) need equipoise at least in studies with more than minimal risks.
Ideally, this equipoise is also present in patient-participants.
In pediatrics, data on equipoise are lacking. We hypothesize that 1) lack of equipoise at enrolment among parents
may reduce recruitment; 2) lack of equipoise during participation may reduce retention in patients assigned to a
less favoured treatment-strategy.
Methods: We compared preferences of parents/patients at enrolment, documented by a questionnaire (phase
1), with preferences developed during follow-up by an interview-study (phase 2) to investigate equipoise of
child-participants and parents in the BeSt-for-Kids-study (NTR 1574). This trial in new-onset Juvenile Idiopathic
Arthritis-patients consists of three strategies. One strategy comprises initial treatment with a biological disease-
modifying-antirheumatic-drug (DMARD), currently not standard-of-care. Semi-structured interviews were
conducted with 23 parents and 7 patients, median 11 months after enrolment.
Results: Initially most parents and children were not in equipoise. Parents/patients who refused participation,
regularly declined due to specific preferences. Many participating families preferred the biological-first-strategy.
They participated to have a chance for this initial treatment, and would even consider stopping trial-participation when
not randomized for it. Their conviction of superiority of the biological-first strategy was based on knowledge from
internet and close relations. According to four parents, the physician-investigator preferred the biological-first-strategy,
but the majority (n = 19) stated that she had no preferred strategy. In phase 2, preferences tended to change to the
treatment actually received.
Conclusions: Lack of equipoise during enrolment did not reduce study recruitment, mainly due to the fact that
preferred treatment was only available within the study. Still, when developing a trial it is important to evaluate
whether the physicians’ research question is in line with preferences of the patient-group. By exploring so-called
‘informed patient-group’-equipoise, successful recruitment may be enhanced and bias avoided.
In our study, lack of equipoise during trial-participation did not reduce retention in those assigned to a less
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favoured option. We observed a change for preference towards treatment actually received, possibly explained
by comparable outcomes in all three arms.
Keywords: Equipoise, Clinical trial, Juvenile idiopathic arthritis, Therapeutic strategy study, Biologicals, Treatment-
to-target, Tight control, Individual, Patient-group, Randomization, Pediatric rheumatology, Informed consent
Background
It is an ethical requirement that physician-investigators
provide research-participants the best treatment available
in randomized controlled trials (RCT) [1–3]. In a clinical
trial comparing different treatment strategies there should
be uncertainty regarding preferred treatment option con-
sidering therapeutic efficacy and safety [1–4]. This is
called equipoise. ‘Individual equipoise’ implies that the in-
dividual physician-investigator must possess this genuine
uncertainty [1]. Affected by preliminary results during a
trial, a physician-investigator could develop a preference
which might lead to a perceived conflict whether the best
treatment known is actually provided. Therefore, Freed-
man described ‘clinical equipoise’ as genuine uncertainty
in the medical expert community instead of genuine un-
certainty in the individual physician-investigator [1]. Clin-
ical equipoise allows the physician-investigator to collect
evidence to convince the expert community of either su-
periority. Critics on clinical equipoise argue that this con-
cept needs to be transformed to adapt to forward modern
health care: if the potential social value of a study is rele-
vant and participants are not exposed to excessive net
risks, clinical equipoise can be amended [5, 6]. Kimmel-
mann questions whether equipoise should be rethought as
a prima facie principle rather than an absolute one [7] and
we agree on that. Miller et al. even question the necessity
of equipoise [8].
Literature suggests that not only the medical expert com-
munity should be in equipoise but also patient-participants
(and their parents, if children are concerned) [8, 9].
In pediatrics, experience with clinical equipoise is lim-
ited [10, 11]. In pediatric oncology, parental and phys-
ician equipoise has been scarcely studied [12, 13].
Difficult protocols, strong emotions and the parents’ de-
pendency on their child’s physician are reasons for often
lacking parental equipoise. In pediatric rheumatology,
treatment preferences among physicians have been stud-
ied by Hugle et al. [14] revealing that availability and
funding influenced physicians’ choices. A discrete choice
experiment explored parents preferences in juvenile
idiopathic arthritis in daily clinical care [15]. Parents
have strong preferences for treatments that reduce pain
and improve daily functioning, regardless of side effects.
With increasing disease duration, parents preferences fo-
cused on therapeutic effectiveness. Little is known about
patient-participant-equipoise or parent-equipoise [9, 12,
16] in pediatric clinical research on chronic diseases.
More insight in this equipoise is particularly important




In this study we aimed to evaluate (1) the preferences
of Juvenile Idiopathic Arthritis (JIA) patients aged 12
years and older, and their parents for a certain treat-
ment strategy in the setting of a randomized clinical
trial, and (2) the influence of the informed consent
procedure on these preferences.
Context BeSt for kids study
The trial concerned the BeSt for Kids study (Dutch Trial
Register NTR 1574), a multicenter, randomized,
single-blinded two year follow-up clinical trial compar-
ing time- to-inactive disease and time-to-flare in se-
lected categories of newly diagnosed JIA
patient-participants. In this study patient-participants
(age between 2 and 16 years) with a maximum of 18
months of complaints and 1) oligoarticular JIA 2)
Rheumatoid Factor (RF) negative polyarticular JIA and
3) Juvenile Psoriatic Arthritis, (6) with active disease re-
quiring treatment with a disease modifying antirheu-
matic drug (DMARD) according to the treating
pediatric rheumatologist were randomized in three
treatment strategies. These strategies are.
1. initial monotherapy with sulfasalazine or
methotrexate,
2. initial combination therapy with methotrexate and
prednisone bridging,
3. initial combination therapy with methotrexate and
etanercept.
In the study protocol subsequent steps to reach
inactive disease are dictated in case of insufficient re-
sponse in all three arms. An additional file contains the
summary of the protocol initial treatments and subse-
quent treatment steps [see Additional file 1].
Data on efficacy of the different individual DMARD
is available in literature [18–20]. No data existed before
and during inclusion on the superiority of either of
those strategies.
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The treatment was single-blinded: the periodic assess-
ment of disease activity was performed by a physiother-
apist, unaware of the allocated treatment, but patient
and physician were not blinded.
The informed consent procedure for inclusion in the
BeSt for Kids study consisted of at least one visit to the
outpatient clinic, with an oral explanation by the attend-
ing physician and the research nurse and complementary
written information. In addition to the patient- subjects
information form (PIF), which is available as supplemen-
tary file [see Additional file 2], all newly diagnosed pa-
tients with juvenile idiopathic arthritis are referred to
http://www.printo.it for general information on juvenile
idiopathic arthritis. Besides that, patients and parents
had several days to week(s) between receiving written
PIF and actual enrolment. The BeSt for Kids was ap-
proved by the Institutional Review Board at Leiden Uni-
versity Medical Center and written informed consent
was obtained from all participants before enrolment.
Design equipoise study
Phase 1 (questionnaire)
When parents and children (aged 12 years and older)
consented to participate in the trial, they were random-
ized. Subsequently the physician completed the Case
Report Form which included a questionnaire asking
parents and patients for their preferred strategy before
actual allocation to the strategy. This questionnaire has
been added as supplementary file [see Additional file 3].
To diminish bias by only asking participating parents
and patients we additionally collected the reasons for
not participating in the study.
Phase 2 (interview study)
We conducted an interview study with parents and
patient-participants aged 12 years and older participating
in the BeSt for Kids study which was designed after of
the onset of the study. Parents and patient-participants
were informed of the interview by a letter asking them
to participate in the interview study. All patients en-
rolled in the study at that time point (n = 29) were con-
tacted by telephone for participation, which lead to an
appointment for an interview with a short questionnaire.
This questionnaire is added as supplementary file [see
Additional file 4]. To facilitate families, the actual inter-
view was held in the hospital or at home by choice.
One-to-one, semi-structured interviews were conducted
with the parents and patient-participants.
We choose the age of 12 years for patient interviews
since in the Netherlands by law children from the age
of 12 years old are actively involved in their healthcare
related decisions in consultation with their parent(s) or
guardian(s).
This study and the consent procedure were approved
by the IRB of the Leiden University Medical Center.
Verbal consent was obtained from both parents and
children, according (no capital needed) to the Dutch
Law (Medical Research Involving Human Subjects Act
(WMO) and Medical Treatment Agreement Act
(WGBO) for studies with negligible risk and burden
only verbal consent is necessary.
Interview procedure and analysis
All parents and patient-participants were interviewed
by researcher B.Y. Interview topics and questions were
formulated after evaluation of the relevant literature.
Topics were: 1 Evaluation of the Informed consent
procedure, 2 Preference for treatment strategy, 3 Com-
ments on preference, 4 Impression of physicians’ pref-
erence and 5 Main reasons for participation in BeSt for
Kids study. Interviews contained closed-ended as well
as open-ended questions. Using the latter, participants
could elaborate on their answers on closed-ended ques-
tions. Interviews lasted between 20 and 45 min.
The interviews were recorded and transcribed verba-
tim. Data analysis of the interviews was based on the
constant comparative method [21, 22]. One of the re-
searchers encoded the full transcripts manually by iden-
tifying and labeling discrete units of texts which refer
to one or more concepts relevant to the study. Through
comparison across transcripts, open codes were devel-
oped into higher order themes to provide a framework
for coding subsequent transcripts. P.H.M. and M.d.V.
coded a random sample of the interviews to check for
consistency and adequacy of the framework. When no
new thematic content was found in the parent inter-
views, subject enrolment was stopped. This process,
called thematic saturation, is a well-described qualita-
tive method to avoid unnecessarily large and repetitive
data sets [23, 24].
Finally, representative quotations from parents and
physicians were chosen to demonstrate the themes
identified.
Results
Phase 1 questionnaire: Preference at inclusion in the BeSt
for kids study
During recruitment, we have received information on
reasons for refusal in 15 out of 36 refusals (Table 1). In
total 94 children were randomized in the BeSt for Kids
study.
All parents and children aged 12 and older were
asked during enrolment in the BeSt for Kids study, be-
fore randomization, whether they hoped to be assigned
to a particular treatment strategy. At the start 46% of
parents of all enrolled patient-participants (n = 94)
expressed to have no preference, 34% hoped for
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assignment to strategy 3 (initial etanercept with metho-
trexate) and 7% hoped against assignment to strategy 3.
Primary aversion was highest for the second strategy
(25%) due to a dislike of prednisone (data not shown).
To compare, reasons for refusal to participate in the
study were documented in 15/36(42%) and are sum-
marised in Table 1. Multiple reasons were expressed,
ranging from strong preference to dislike for a particu-
lar arm. Six out of 36 (17%) expressed explicit prefer-
ences or dislike of arm 1 or arm 3.
Phase 2: Interview study
Figure 1 shows the recruitment of parents and patient-
participants in our interview study. Twenty-nine patients
were approached for the interview-study, finally 23 inter-
views were conducted with 22 mothers and 1 father.
Parents had a mean age of 40.0 years (range 32–51 years)
and patient-participants 14.3 years (range 12–17 years).
All participants were Dutch speaking. Two parents were
divorced, the rest was married. The education level was
middle level high school (n = 1), high level high school
(n = 1) intermediate vocational (n = 1), secondary voca-
tional (n = 8) and advanced vocational/university (n = 12).
Between inclusion in the BeSt for Kids study and the
interview (Phase 2) was a period of mean 11.8 (3.4–19.1)
months.
Table 1 Summary of patients/parents who refused to
participate in the BeSt for Kids study with reasons for refusal
Number of patients who refused to participate n = 36
Known reason for refusal of trial participation n = 15 (42%)
Preference for arm 1 1
Preference for arm 3 1
Fear in general 1
Do not want to randomize at all 2
Do not want to receive prednisone or injections 2
Do not want to receive arm 3 2
Too busy to participate 2
Don’t feel like it 2
No reason mentioned when asked 2
Best for Kids participants
Approached 
n=29
Parents of patients ≤ 12 years
n=18
Parents of patients ≥12 years
n=11
EXCLUDED
Refusal by parent 
● Lack of time
n=3
EXCLUDED
Refusal by parent or patient
● Lack of time




Interviewed parents and patients
n=7
DATA AVAILABLE FOR ANALYSIS
● Interview one parent n= 21
● Interview two parents n= 1 
● Interview patient n= 7
Total
Interview parents n=23
Interview Patients ≥ 12 years n=7
Fig. 1 Recruitment of parents and patients
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Parent 14 and 15 are parents of the same patient. In
parent number 1–16 only parents were interviewed. In
parent number 17–23 both parent and patient were
interviewed.
The concepts that were identified in the qualitative
analysis resulted in a framework that comprises the fol-
lowing three themes which will be discussed separately:
I. Non-participation or withdrawal is not without
consequences.
II. The conviction of superiority of the ‘experimental’
strategy.
III. Participation is in the best interest of the child.
Theme 1: Non-participation or withdrawal is not without
consequences
The majority of parents and children was well aware of
the study design. Results indicated no differences be-
tween parental and patient-participants’ understanding
concerning study name, duration, aim and number of
treatment strategies. Although almost all participants
(parents n = 23, patient-participants n = 7) knew that
they were allowed to withdraw from the study at all
times, seven parents and four patient-participants be-
lieved that stopping the trial would have consequences
for the treatment in terms of less quality and quantity
of the patient-participant care.
(Parent 8) Sure it has consequences. This means he is
not being looked after […].
(Parent 18) Now she gets such good care. That would
be less; there would be less time and less checkups.
Two parents and three patient-participants argued that
it would have consequences because initial treatment
with etanercept is not covered by insurance companies
outside the trial.
(Parent 19) Yes I think so. If you stop then you receive
no further medication.
(Patient-participant 17) It could be that the insurance
company requires you to pay for the drugs.
(Patient-participant 23) Because if I stop it has
consequences for my treatment. Because I could never
get this treatment by the insurance.
Theme 2: The conviction of superiority of the
experimental strategy
All parents (n = 23) expressed that they had a preference
for a particular treatment strategy. Fourteen parents
(61%) preferred the third strategy (initial etanercept with
methotrexate) whereas 3 (13%) preferred the first strategy
(initial sulfasalazine or methotrexate), one parent preferred
the second strategy (initial methotrexate and prednisone
bridging), one parent preferred the first or second strategy
and four (17%) preferred a non-prednisone strategy.
Five of seven patient-participants had a preferred strat-
egy. Three of them preferred initial etanercept with
methotrexate (third strategy) and two preferred a non-
prednisone strategy. Two of the patient-participants had
no preference.
Generally, as main explanation for their preference for
the 3rd strategy (initial etanercept with methotrexate)
parents and patient-participants stated that they believed
it is the best treatment for JIA given the results of previ-
ous studies [25–28].
(Patient-participant 23) I also wanted that drug
(etanercept), even though we did not know the side
effects. Still, if you hear that it works very well and
that the arthritis completely disappears from your
joints, and therefore it is the best drug, then it seems
obvious to me that you would want that.
(Parent 3) At one moment I read on the internet an
experience by a mother who said she finally got her
teenage daughter back, this was not the crucial reason
but at that moment it confirmed my gut feeling.
(Parent 18) Well we have been searching quite a lot on
the internet and it just gives reasonably good results as
far as they presently know.
Parents and patient-participants indicated that these
beliefs were mainly based on knowledge they had
gained through the internet and from experiences in
their environment.
For both parents and patient-participants reluctance to
prednisone was due to well-known side-effects, mainly
gaining weight.
(Patient-participant 19) What I didn’t want was
prednisone, actually. That’s because my mother had to
use it for a long time and I have seen what it does, it
has a lot of severe side effects.
The majority of parents (n = 19) mentioned that the
physician did not express a preferred treatment strat-
egy. Four parents stated that the physician preferred
etanercept-first strategy.
(Parent 6) The physician had no preference. She
indicated that she was very curious about what the
outcomes of the study will be.
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(Parent 9) Yes, that new medicine. That’s what she
really said. She literally said that they would like to give
it to us. But that simply couldn’t, because of the study
and because insurance companies do not want to pay.
(Parent 14a) I thought that the physician absolutely
had no preference at all.
(Parent 16) Because of course, I didn’t know it yet, we
were confronted with a diagnosis that really was
unexpected. [ … ] So I had the impression that they
were very enthusiastic about this new drug, and that
the study gave us the opportunity to get it earlier.
One of the patient-participants thought that the phys-
ician preferred initial treatment with etanercept. One
did not remember and five recalled that the physician
did not have a preference.
Theme 3 participation is in the best interest of the child
Although some families stated that they (also) partici-
pated in the BeSt for Kids study to help the good cause
of research and therefore to support the next genera-
tions of JIA patients (n = 6 parents), many families
expressed personal reasons to participate.
(Parent 4) […] It was more the extra attention[….]
However, also a little bit for the good cause, of course,
that other patients could benefit from it as well in the
long term.
Seven parents joined the study because they assumed
that in participating, their child would be more closely ob-
served. Parents also participated for the best prospect of
their child (n = 5), hoping that joining the study was the
best they could do. Five parents stated that their reason
for participation was to have the opportunity for initial
treatment with etanercept (strategy 3). One mother even
expressed that she would have withdrawn from the trial if
her child had not randomized in their preferred strategy.
(Parent 23), Had I drawn strategy 2, I would have
immediately stopped. Then I would have chosen my
own direction with my child, off course in consultation
with the physician In that case I would not want to
participate in the study, and then you should have to
work with the available resources.
(Parent 5) [… .]Of course there are many benefits as a
result of taking part …
Patient-participants also joined the study because of
a chance for initial treatment with etanercept (strategy
3)(n = 3).
(Patient-participant 23) I believe that our main goal
was that we could get the really good medication.
Two patient-participants only mentioned their wish
to recover (n = 2) without giving another reason for
participation. Two patient-participants chose to partici-
pate for the good cause of research.
Changing preferences
When comparing the results from phase 1, before
randomization, to the results during the interview
(phase 2), half of the parents (11/23) showed a differ-
ent preference in the interview compared to their
opinion at enrolment, from which 6 out of 11 changed
to preference of the actual enrolled treatment strategy,
mainly increasing preference for arm 1 and arm 3.
Eight out of 23 (36%) had a persistent preference for
strategy 3. Two tables illustrate the changing prefer-
ences according to the treatment actually enrolled to
[see Additional file 5: Tables S2 and S3].
Discussion
The results of our interview study demonstrate that at
enrolment (phase 1) many parents and children in the
BeSt for Kids study are not in equipoise, because most
of them hold the conviction that strategy 3, initial com-
bination therapy with methotrexate and etanercept, is
medically superior to the other strategies, as described
in theme 2. In the majority of parents this is not caused
by an assumed preference of the physician-investigator
but by information on the various treatment possibil-
ities obtained from other sources.
This is an evaluation of parents’ preferences for
treatment strategies by a questionnaire at enrolment
(phase 1) as well as by interviews several months into
the different treatment strategies (phase 2). When
comparing the preferences at the two time points we
conclude that parents increasingly preferred initial
combination therapy with etanercept and methotrexate
and disliked taking prednisone.
Having a preferred strategy in general increased from
62% at enrolment to 100% of parents during the study
period. This difference can be explained by the fact that
the interview took place almost a year after study enrol-
ment so that perception can be modified by experience.
Initially preferences focused on fear of side effects of
prednisolone and suspected superiority of the initial
etanercept (arm 3). In phase 2 preferences shifted to
mainly arm 1 and arm 3, often the actual strategy chil-
dren received. Parents and children by then seemed to
focus on effectiveness of the therapy received, as was
described previously [15]. This result is also consistent
with previous results in the BeSt-trial in rheumatoid
arthritis patient-participants [29] where patients clearly
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preferred initial combination therapy with infliximab
and disliked taking prednisone.
Parents have many motivations when deciding
whether or not to let their child enter a randomized
clinical trial. They will not easily agree on
randomization because an ethics committee has ap-
proved the study [30, 31]. The primary responsibility of
parents is to act in (what they think is) the best interest
of the child, and the choice to enter a trial is based
both on ‘objective‘probabilities of trial outcomes and
on the value that parents and patient-participant place
on those outcomes [32]. Also in our study, the main
reason for parents to participate in the BeSt for Kids
study was to support the best interest of their child
(theme 3). For some parents, the trial represented the
prospect of receiving a new, not routinely available
treatment with a potentially important direct benefit to
their child as was recognized previously as an import-
ant motivator for parents and patients to participate in
studies [30, 33]. Etanercept is in the Netherlands not
reimbursed as first treatment option. Therefore, as ini-
tial treatment, it was only available within the trial and
parents may consent to their child’s entry because of
the chance of receiving these assumed benefits [30, 34].
It may cause them firstly to anticipate remorse for not
at least trying to obtain this new treatment through
trial participation, and secondly to expect consequences
when withdrawing during the study. This is under-
standable from their perspective as guardian of the
interests of their child [12]. One could imagine a differ-
ent outcome in cases where parents prefer a standard
treatment which is routinely available outside of re-
search. Additionally, a short course of Prednisolone is
regularly applied in daily patient care in Juvenile idio-
pathic arthritis patients as bridging therapy, since
methotrexate is a slow-acting DMARD.
Whatever trial strategy parents think is better for their
child, their preference shows that the idea of clinical
equipoise held by the expert medical community is not
directly transferable to the parent setting as a proxy [35].
For parents and children the different strategies of a trial
are often not in equipoise, because they hold the convic-
tion that one strategy is medically superior [33, 34, 36].
Although in this study many parents, but not all, were
prepared to enter a study (and continue participation)
when they had preferences for therapy other than what
they received, this lack of equipoise could be a problem
for recruitment in RCT’s.
Recently it was suggested by Whybrow [35] to take
an epidemiological approach to the concept of equi-
poise situating it as a measurable characteristic of a tar-
get patient-group. We argue that both types of patient
equipoise (individual and patient-group) are relevant at
different time points in the clinical research setting.
Individual patient equipoise is relevant when actually
contemplating trial participation between physician and
patient/parent. Individual values need to be discussed
and exchanged to explore possible trial participation.
Informed patient-group equipoise is relevant, and we
would say even necessary, in the phase of developing a
trial to evaluate whether the research question the
physician wants to answer is in line with the prefer-
ences of the patient group.
If scientists are aware of the consequences of strong
patient preferences by evaluating the patient group equi-
poise they can anticipate to the possible lack of inclu-
sions in a trial. One example with a deviating clinical
expert equipoise and patient group equipoise is the
CONCERT study. The CONgenital Cmv: Efficacy of anti-
viral treatment in a Randomized controlled Trial (CON-
CERT) study aimed to evaluate the efficacy of antiviral
therapy in congenital cytomegalovirus (CMV) infection
in a randomized clinical trial (clinical trials.gov
NCT01655212). The inclusion period was terminated
prematurely due to lack of inclusions since parents did
not want to randomize for placebo treatment (personal
communication). ‘Placebo’ versus ‘treatment’ is different
from 3 different treatment strategies. Therefore every
particular study design may need a different approach in
case of lacking equipoise on the level of the informed
patient group. Preferably the informed patient group is
involved early in the study design to prevent lack of in-
clusion in studies. As an example, the future research
agenda in JIA will be created according to the James
Lind Alliance method [37], to create research that really
matters to parents/patients and caregivers and this will
potentially increase enrolment in future studies.
Conclusion
Parental and patient equipoise is important to investi-
gate to enhance recruitment for and retention in stud-
ies involving children. In our study, lack of equipoise
during enrolment did not reduce study recruitment,
due to the fact that preferred treatment was only avail-
able within the study. Still, when developing a trial it is
important to evaluate whether the research question
the physicians want to answer is in line with the prefer-
ences of the patient group. By exploring ‘informed
patient-group’ equipoise successful recruitment may be
enhanced and bias may be avoided.
Lack of equipoise during participation in our long
term follow-up trial did not reduce retention in those
who were assigned to a less favoured option, probably
related to the dynamic treatment-to-target study de-
sign. We observed a change for preference towards
treatment actually received, possibly explained by
favourable outcomes in all three arms [38].
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